Insights On Partnering

  1. Harnessing Innovative Technologies For Clinical Trials Involving Emerging And Re-Emerging Infectious Diseases

    This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola.

  2. Genomic Assays For Clinical Development: Identifying The Right Approach

    Learn more about different genomic assays that can be used during clinical development and which ones are right for your study.

  3. The End To End Importance Of Selecting The Right Biomarker In Cancer Studies

    A critical component in the fight against cancer and optimizing treatment outcomes for patients.

  4. Shifting From One Drug For All Patients To Personalized Genomics-Based Therapeutic Options

    Discover how a comprehensive personalized genomics strategy can help you identify the patients who would most likely benefit from a treatment and suffer the least side effects, ensuring the right drug is used in the right patient at the right time.

  5. Zika Vaccine Research

    Discover the role of the central laboratory in Zika vaccine development and how you can proactively avoid challenges along the development continuum.

  6. New Approaches For Malaria Vaccine Development

    How advances in genetic engineering have brought new hope to conquering malaria.

  7. Translating Data Into Insights With Bioinformatics

    Learn what bioinformatics offers to precision medicine and immuno-oncology.

  8. Genomic Based Solutions For Your Immuno-oncology Drug Development Needs

    Learn how genomics-based biomarker approaches can empower the success of your immuno-oncology clinical development programs by implementing a tailored biomarker strategy.

  9. Integrating Third-Party Lab Management To Streamline Clinical Development

    Real world experiences, pitfalls and best practices that can improve the efficiency of clinical development when centralizing and managing third party vendors.

  10. Clinical Trials Laboratories In The Immuno-Oncology Setting

    The development of immuno-oncology (I/O) medicines offer a new era of treatment options for physicians and patients. However, the level of sophistication required for biomarker selection, trial design, technology implementation, testing, and commercialization planning is unprecedented. Learn more about how clinical trial laboratories are utilizing multiple technologies and solutions to support immuno-oncology clinical development.